Companies:
51,160
Total Market Cap:
148594285682501.02
Global Rank
#1495
Country Rank
#49
Market Cap
14.27 B
Price
20.52
Change (%)
0.19%
Volume
4.61 M
Roivant Sciences Ltd.'s latest marketcap:
14.27 B
As of 11/19/2025, Roivant Sciences Ltd.'s market capitalization has reached $14.27 B. According to our data, Roivant Sciences Ltd. is the 1495th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 14.27 B |
| Revenue (ttm) | 20.33 M |
| Net Income (ttm) | -373,968,000 |
| Shares Out | 695.49 M |
| EPS (ttm) | -0.54 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 11/10/2025 |
Market Cap Chart
Data Updated: 11/19/2025
Roivant Sciences Ltd.'s yearly market capitalization.
Roivant Sciences Ltd. has seen its market value grow from $521.58 M to $14.27 B since 2020, representing a total increase of 2,636.20% and an annual compound growth rate (CAGR) of 96.87%.
| Date | Market Cap($) | Change (%) | Global Rank |
|---|---|---|---|
| 11/19/2025 | $14.27 B | 65.72% | 1495 |
| 12/31/2024 | $8.61 B | -4.61% | 1956 |
| 12/29/2023 | $9.03 B | 55.76% | 1767 |
| 12/30/2022 | $5.8 B | -18.13% | 2366 |
| 12/31/2021 | $7.08 B | 1257.32% | 2418 |
| 12/31/2020 | $521.58 M | 11370 |
Company Profile
About Roivant Sciences Ltd.
Roivant Sciences Ltd. is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative medicines in inflammation and immunology.
Key Offerings
- Vants: A unique business model for developing and commercializing medicines, targeting biopharmaceutical businesses, discovery-stage companies, and health tech startups.
- VTAMA: A novel topical treatment approved for psoriasis and in development for atopic dermatitis.
- IMVT-1402 & Batoclimab: Fully human monoclonal antibodies targeting the neonatal Fc receptor for IgG-mediated autoimmune conditions.
- Brepocitinib: A TYK2/JAK1 inhibitor in development for dermatomyositis, non-infectious uveitis, and other therapies.
- Namilumab: An anti-GM-CSF monoclonal antibody in Phase 2 trials for inflammatory and autoimmune diseases.
- Delivery Platforms: Includes lipid nanoparticle and ligand conjugate platforms for advanced drug delivery.
Strategic Collaborations
- Partnership with Boehringer Ingelheim for RNA-specific adenosine deaminase 1 targeting compounds.
- License agreement with Japan Tobacco Inc. for tapinarof development in Japan for psoriasis and atopic dermatitis.
Founded: 2014 | Headquarters: London, United Kingdom
Frequently Asked Questions
-
What is Roivant Sciences Ltd.'s (ROIV) current market cap?As of 11/19/2025, Roivant Sciences Ltd. (including the parent company, if applicable) has an estimated market capitalization of $14.27 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Roivant Sciences Ltd. (ROIV) rank globally by market cap?Roivant Sciences Ltd. global market capitalization ranking is approximately 1495 as of 11/19/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.